The MANCO consortium is developing a monoclonal antibody against 2019-nCoV. CR2O is a partner within this consortium and responsible for the clinical operations. For the clinical Phase I study we require a medical monitoring provider.

The procurement includes the following:

• medical monitoring plan (create and update);

• ongoing medical monitoring (safety issue checks, SAE, PD);

• patient profile review and query management;

• site support and medical questions.